Cell Therapy News 17.30 August 15, 2016 | |
| |
TOP STORYHematopoietic Stem Cell Transplantation in Immunocompetent Hosts without Radiation or Chemotherapy The authors showed that host hematopoietic stem cell (HSC) clearance is dependent on Fc-mediated antibody effector functions, and enhancing effector activity through blockade of CD47, a myeloid-specific immune checkpoint, extends anti–c-Kit conditioning to fully immunocompetent mice. The combined treatment lead to elimination of >99% of host HSCs and robust multilineage blood reconstitution after HSC transplantation. [Sci Transl Med] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers hypothesized that mesenchymal stem cells (MSCs) have trophic effects that stimulate recycled chondrons to regenerate cartilage. Searching for a proof of principle, this Phase I clinical trial applied allogeneic MSCs mixed with either 10% or 20% recycled autologous cartilage-derived cells (chondrons) for treatment of cartilage defects in the knee in symptomatic cartilage defect patients. [Stem Cells] Abstract Scientists demonstrated a novel selective depletion (SD) strategy whereby alloreacting T cells are efficiently deleted ex vivo with adenosine. SD was achieved in human leukocyte antigen mismatched cocultures by multiple exposures to 2 mmol/L adenosine over seven days. [Mol Ther] Abstract Ticagrelor and clopidogrel, when applied to a 3-dimentional printed resorbable calcium-triphosphate/hydroxyapatite scaffold implanted in a calvarial bone defect, promoted significantly more bone regeneration than the scaffold alone and as much bone regeneration as BMP-2, a growth factor currently used to promote bone regeneration. [FASEB J] Abstract Switching CAR T Cells On and Off: A Novel Modular Platform for Retargeting of T Cells to AML Blasts Researchers describe a novel modular universal chimeric antigen receptor engineered (CAR T) platform technology termed UniCAR that reduces the risk of on-target side effects by a rapid and reversible control of CAR T-cell reactivity. [Blood Cancer J] Full Article The aim of this study was to determine the therapeutic effects of human placenta derived mesenchymal stem cells on diabetic critical limb ischemia, with or without exogenous insulin administration, and the underlying mechanism of any effect. [Cell Transplant] Abstract Bone Cement with a Modified Polyphosphate Network Structure Stimulates Hard Tissue Regeneration Induced calcification was observed in calcium polyphosphate cement (CpPC)-treated ST2 cells, in contrast with MG-63 and ST2 treated with brushite cement, for which no calcification was observed. In vivo tests using a rat calvarial defect model showed that resorbed CpPC resulted in favorable host responses and promoted bone formation. [J Biomater Appl] Abstract PAX6 MiniPromoters Drive Restricted Expression From rAAV in the Adult Mouse Retina Investigators designed seven small promoters from the human paired box 6 (PAX6) gene and test them in the adult mouse retina using recombinant adeno-associated virus. [Mol Ther Methods Clin Dev] Full Article Recombinant Mumps Virus as a Cancer Therapeutic Agent Scientists describe the development of a reverse genetics system from a major isolate of the Urabe strain mumps virus stock, and the construction and characterization of several recombinant mumps viruses with additional transgenes. [Mol Ther Oncolytics] Full Article | |
| |
REVIEWSThe Significance of Cell-Related Challenges in the Clinical Application of Tissue Engineering The reviewers highlight the main confounding issues associated with cells in tissue engineering and how these issues may hinder the advancement of therapeutic tissue engineering. [J Biomed Mater Res A] Abstract Visit our reviews page to see a complete list of reviews in the cell therapy research field. | |
| |
INDUSTRY NEWSJuno Therapeutics, Inc. announced that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. for a novel, fully-human binding domain targeting B-cell maturation antigen, along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma. [Juno Therapeutics, Inc.] Press Release Adverum Biotechnologies, Inc. and Editas Medicine, Inc. announced a collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. This collaboration brings together Adverum’s next-generation adeno-associated viral vectors for use with Editas’ leading genome editing technologies to create a series of novel therapies for debilitating eye diseases that have poor therapeutic options. [Adverum Biotechnologies, Inc.] Press Release RetroSense Therapeutics LLC announced that the low dose cohort of patients has been safely dosed in the initial clinical trial to evaluate the safety of RST-001. No inflammation or ocular adverse events were seen in any of these patients, and biological activity has been confirmed. [RetroSense Therapeutics LLC (PR Newswire Association LLC)] Press Release Shire plc, continuing on Baxalta’s long-standing commitment to the bleeding disorder community, announced the U.S. launch of VONVENDI, the only recombinant treatment for adults living with von Willebrand disease. [Shire plc] Press Release Bellicum Announces BPX-501 European Regulatory Updates Bellicum Pharmaceuticals, Inc. announced that the European Commission has granted orphan drug designations for both its lead T-cell therapy product candidate BPX-501 for treatment in hematopoietic stem cell transplantation, and for activator agent rimiducid for the treatment of Graft vs. Host Disease. [Bellicum Pharmaceuticals, Inc.] Press Release iCell Gene Therapeutics announced that the US Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 for the treatment of peripheral T-cell lymphoma. [iCell Gene Therapeutics] Press Release Tissue Regeneration Therapeutics Inc. (TRT) announced that a team of Canadian researchers has for the first time shown that TRT’s engineered mesenchymal stromal cell product can be used to deliver therapeutically useful monoclonal antibodies more effectively than administration of the mAbs themselves. [Tissue Regeneration Therapeutics Inc. (PR Newswire Association LLC)] Press Release Sorrento Therapeutics, Inc. announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation, has been appointed to the position of Chief Medical Officer and President of Clinical Development. [Sorrento Therapeutics, Inc.] Press Release Marken Announces New Operations Center in Zurich Marken announced the opening of their latest GDP-compliant operations center in Zurich, Switzerland, responding to increased demand from local pharmaceutical companies with growing clinical development programs. [Marken Switzerland AG] Press Release | |
| |
POLICY NEWSSpiking Genomic Databases with Misinformation Could Protect Patient Privacy Large genomic databases are indispensable for scientists looking for genetic variations associated with diseases. But they come with privacy risks for people who contribute their DNA. A 2013 study showed that hackers could use publicly available information on the Internet to identify people from their anonymized genomic data. [Nature News] Editorial UK Government Gives Brexit Science Funding Guarantee British scientists say they’re relieved by a government promise to guarantee them funding for existing EU research projects, even after the country leaves the European Union. But the reassurance only partly allays concerns about Brexit’s effect on UK science. [Nature News] Editorial Candidate Cancer Drug Suspected After Death of Three Patients at an Alternative Medicine Clinic A new type of cancer drug developed at Johns Hopkins University in Baltimore, Maryland, but not yet tested in clinical trials may have triggered the deaths of three patients who were undergoing an alternative cancer treatment by a nonmedical practitioner in Germany. [ScienceInsider] Editorial
| |
REGULATORYFDAInfectious Disease Next Generation Sequencing Based Diagnostic Devices: Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers; Draft Guidance for Industry and Food and Drug Administration Staff; Extension of Comment Period (FR Doc. No:2016-19109) Notice Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Applications for Food and Drug Administration Approval To Market a New Drug: Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Valid or Will Not Be Infringed (FR Doc. No:2016-19385) Notice
| |
EVENTSNEW 7th International Conference on Stem Cells and Cancer (ICSCC-2016): Proliferation, Differentiation and Apoptosis NEW International Conference on Stem Cell Engineering 2016 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW PhD Studentship – Fibrosis (National University of Ireland, Galway) Postdoctoral Fellow – Tumor Immunology and Head and Neck Cancer (University of Lausanne) Postdoctoral Fellow – Tumor Immunology and T Cell Differentiation (University of Lausanne) Scientist/Sr. Scientist – Nanoparticle Research, Delivery Innovation (Moderna Therapeutics) Research Fellow – Hematology and Epigenetics (University of Edinburgh) Research Fellow – Hematology (Mayo Clinic) Postdoctoral Fellow – Pluripotent Stem Cell Technology (University of California Davis) Associate Member – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center) Faculty Position – Cancer Immunology (University of New Mexico) Postdoctoral Fellow – Oxidative Lung Injury (Temple University) Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Cell Therapy News Volume 17.30 | Aug 15 2016